CYS TIC FIBROSIS RELATED DIABETES IN ADOLESCENTS

DV ir la n,1LS o c h i r c a ,2AC h i r i a c ,3SS c i u c a .

1Department of Pediatrics, State Medical and Pharmaceutical University Nicolae Testemitanu, Chisinau, Moldova; 2Department of Endocrinology, National Children’s Hospital “Emilian Cotaga”, Chisinau, Moldova; 3Cystic Fibrosis Center, Mother and Child Center, Chisinau, Moldova

10.1136/archdischild-2014-307384.736

Background Cystic fibrosis related diabetes (CFRD) is a combination between reduced insulin secretion and peripheral insulin resistance that only people with cystic fibrosis can get. CFRD is associated with a decline in lung function, poor nutritional status and high mortality rate.

Aim Study of the clinical course and therapeutic management in adolescents with CFRD.

Methods We present 2 cases of CFRD in a female patient (15 years old) and a male patient (17 years old) hospitalised at the CF Centre. The diagnosis of CF was confirmed by positive sweat test (Macroduct USA), identification of CFTR mutation (F508del/F508del), small amounts of elastase in stool. Confirmation of diabetes was achieved by a blood glucose test, blood glucose profile, glycosylated Hb, C peptide, glucose and ketones in urine.

Results On the background of pulmonary exacerbation, both patients had hyperglycemia (9.8/14.1 mmol/l). Subsequently, it triggered clinical syndromes suggestive for diabetes - polydipsia, polyuria, weight loss. Glycemic profile variations 7.8–15.8 mmol/l in boy and 10.4–21.0 mmol/l in girl. Glycosylated Hb values were high (7.3/14.1%) and C-peptide values were low (0.624/0.513). Glucose concentration in urine was 7.3/37.1 g/l and ketones was not detected. Diabetes treatment was performed with Insulin (Glargine, Aspart, Human), which produced clinical benefits by achieving glycemic and clinical syndromes control.

Conclusions Patients with CFRD shows a specific clinical framework and require a strict medical diet control and surveillance of the insulin therapy, case that differs from the other types of diabetes. If early introduced, it significantly improves life expectancy towards these patients.

VITAMIN D STATUS IN CHILDREN WITH TYPE 1 DIABETES

N Makieieva, V Tsymbal, T Ishchenko, N Buzhynska.
Pediatrics #1 and Neonatology, Kharkov National Medical University, Kharkov, Ukraine

10.1136/archdischild-2014-307384.737

Background and aims Serum vitamin D (sVD) deficiency may contribute to the development and progression of diabetic nephropathy (DN). Research has shown urinary vitamin D binding protein (uVDBP) excretion is increased after renal injury, and is associated with tubulointerstitial damage. Animal studies suggested that sVD deficiency may be associated with urine loss due to kidney damage. The aim was to test associations of sVD with levels of uVDBP, urinary vitamin D (uDV).

Methods 42 children aged 6–17 years with type 1 diabetes were examined: 24 normoalbuminuric patients (1st group) and 18 microalbuminuric (2nd group). 15 healthy children were included in controls. We measured serum and urine 25(OH)D levels, uVDBP concentrations and tested their correlations.

Results sVD levels were decreased in the patients of the 1st and 2nd groups, compared with controls (22.03 (17.23; 24.44) and 14.42 (12.02; 19.63), compared with 30.65 (28.45; 35.05) ng/ml, respectively) (p < 0.001)). uVD levels were elevated in the patients of the 1st and 2nd groups, compared with controls (179.5 (147.0; 189.0) and 219.0 (216.0; 222.0), compared with 125.0 (116.5;136.0) ng/ml, respectively) (p < 0.001)). uVD levels were increased in the patients of the 1st and 2nd groups, compared with control group (3.2 (2.9; 3.3) and 3.9 (3.7; 4.1), respectively).
CIRCULATING OXIDISED LDL AND INSULIN RESISTANCE AMONG OBSESE SCHOOL STUDENTS

N Hassan, S El-Masany, M Abu shady, 2F Abdel-Hamid, 3A Anwar. 1Biological Anthropology, National Research Centre, Giza, Egypt; 2Child Health, National Research Centre, Giza, Egypt; 3Medical Biochemistry, National Research Centre, Giza, Egypt

Abstract PO-0068 Table 1

HbA trends (%) 95% CI (%)

G1 (a vs. b) +1.78 0.24–3.32
G2 (a vs. b) -0.06 0.52–0.40

CI, Confidence Interval

Conclusions No significant difference of HbA in two groups post diagnosis; mean HbA1C level (p = 0.082). Comparing the changes over time in the two groups, an increase of HbA1C of 1.78 (Table2) percentage points in G1 (without intensive monitoring) was significantly greater than the decrease of 0.06 percentage points in G2 (p = 0.008).

Discussion Intensive initial management of type 1 Diabetes can significantly reduce future HbA1C. We aim to follow G2 over next 5 years to establish that an improved metabolic memory-could reduce HbA1C levels over longer periods.

TERMINAL DELETION OF CHROMOSOME 15Q RESULTS IN HAPLOINSUFFICIENCY OF THE IGF-1 RECEPTOR AND MARKED ELEVATION OF IGF-1

A O’Ronan, 1N McGrath, F Sharif, M O’Grady. Paediatrics, Midland Regional Hospital Mullingar, Mullingar, Ireland

Abstract PO-0069 Table 1

HbA1C post diagnosis quarter (Mean) (Number/%) Reduction of HbA1C levels achieved (%)

G1a 8.67(7.87–9.48) 11(78) 21
G1b 10.45(9.10–11.81) 13(93) 7
G2a 7.87(7.29–8.44) 12(80) 40
G2b 7.81(7.33–8.29) 13(85) 35

CI, Confidence Interval

Conclusions No significant difference of HbA in two groups post diagnosis; mean HbA1C level (p = 0.082). Comparing the changes over time in the two groups, an increase of HbA1C of 1.78 (Table2) percentage points in G1 (without intensive monitoring) was significantly greater than the decrease of 0.06 percentage points in G2 (p = 0.008).

Discussion Intensive initial management of type 1 Diabetes can significantly reduce future HbA1C. We aim to follow G2 over next 5 years to establish that an improved metabolic memory-could reduce HbA1C levels over longer periods.